Compare · AXDX vs BRKR
AXDX vs BRKR
Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXDX and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $9.81B, about 49.8x AXDX ($197.2M).
- Over the past year, AXDX is down 93.2% and BRKR is down 7.9% - BRKR leads by 85.3 points.
- BRKR has hit the wire 11 times in the past 4 weeks while AXDX has been quiet.
- BRKR has more recent analyst coverage (21 ratings vs 1 for AXDX).
- Company
- Accelerate Diagnostics Inc.
- Bruker Corporation
- Price
- $0.14+59.82%
- $36.55+0.74%
- Market cap
- $197.2M
- $9.81B
- 1M return
- -93.21%
- +2.11%
- 1Y return
- -93.21%
- -7.88%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 1
- 21
Accelerate Diagnostics Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest AXDX
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
- SEC Form 3 filed by new insider Shalhoub Paul Vincent
- Amendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)
Latest BRKR
- Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
- Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
- Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
- Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
- SEC Form 4 filed by Munch Mark
- Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
- SEC Form DEFA14A filed by Bruker Corporation
- SEC Form DEF 14A filed by Bruker Corporation
- SEC Form 3 filed by new insider Bernard Thierry
- Bruker Corporation filed SEC Form 8-K: Leadership Update